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Abstract
Background: We studied Y-STRUT® (Hyprevention, France), a new percutaneous internal fixation device, in combination
with bone cementoplasty to prevent hip fracture.
Methods: Between February 2013 and February 2015, a total of 16 femoral necks in 4 osteoporotic and 12 oncologic
patients have been considered for prophylactic consolidation in this prospective multicentre pilot study involving
4 different hospitals. These consolidations were performed percutaneously under fluoroscopic guidance using Y-STRUT®, a
dedicated internal fixation device. For osteoporotic patients, orthopaedic surgeons performed the prophylactic
consolidations immediately after surgical treatment of a hip fracture (same anaesthesia) in the opposite side. For
oncologic patients, without current hip fracture but considered at risk (Mirels score ≥8), interventional radiologists
performed the procedures. We report the preliminary results of feasibility, safety and tolerance of these preventive
consolidations using Y-STRUT®.
Results: Four patients (mean 83 years old) had prophylactic consolidation because of a severe osteoporosis
(mean T-score −3.30) resulting in first hip fractures. Ten patients (mean 61 years old) were treated because of
impending pathological fractures (mean Mirels score 9) related to femoral neck osteolytic metastases. All the
procedures were performed with success. Wound healing was achieved in all cases with no access site complication.
Radiographic exams performed at 3 months follow-up revealed that Y-STRUT® was well integrated in the bone. For the
osteoporotic cohort, mean pain was 0.9 ± 0.7 at 3 weeks. For the oncologic cohort, it decreases from 3.6 ± 2.9 at
baseline to 2.4 ± 0.9 at 2 months.
Conclusions: Preliminary results demonstrate the feasibility and safety of Y-STRUT® implantation as well as the
tolerance of the device.
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Biomechanical reinforcement
* Correspondence: cornelisfrancois@gmail.com
1Pellegrin Hospital, CHU Bordeaux, Bordeaux, France
2Tenon Hospital, Radiology Department, APHP, Paris, France
Full list of author information is available at the end of the article
© The Author(s). 2016 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cornelis et al. Journal of Orthopaedic Surgery and Research  (2017) 12:27 
DOI 10.1186/s13018-017-0514-2
Background
Hip fracture may occur in several situations, such as
low-energy trauma, osteoporosis or tumour invasion.
Hip fracture is a public health issue due to a large and
growing incidence and its functional and vital repercus-
sions. The worldwide number of hip fractures is esti-
mated at 2 million in 2010, a 26% increase since 1990
[1], and could reach 6.3 million in 2050 [2].
In patients suffering from osteoporosis, this event
often remains highly disabling despite the effectiveness
of surgical treatments and the mortality rate after a first
hip fracture is between 15 and 30% [3]. Moreover, in
20% of cases, this first fracture is followed by a second
fracture of the opposite hip (contralateral) within 5 years
(10% during the first year, 15% at 2 years). These patients,
greatly reduced physically, see their mortality risk increase
to up to 64% in the following 5 years [4]. Hip fracture is,
in most cases, the result of a fall linked to a daily living
activity associated with age-related bone degeneration or
osteoporosis. Osteoporotic elderly women are the most
concerned by hip fracture. Solutions are currently pro-
posed for the prevention of hip fracture related to
osteoporosis. They consist in hip protectors (preventive
treatment with immediate effect) and osteoporosis drug
treatments [5] (long-term preventive treatment). However,
these solutions, ineffective in practice mainly due to lack
of patient adherence to treatment, are not satisfactory.
Biomechanical investigations were performed on some
prophylactic surgical techniques [6, 7], but to our know-
ledge, only one was the object of a clinical trial [8] and is
not marketed.
In patients with metastatic cancer, bone metastases,
mostly localized at the trochanteric region and femoral
neck [9], cause pathological fractures of particularly
serious consequences for these patients, are highly vul-
nerable and are difficult to operate. Life expectancy of
patients who have suffered a fracture of the proximal
femur is estimated to be less than a year on average
[10]. In order to prevent pathological fractures due to
bone metastases, only few options currently exist. A
metallic osteosynthesis fixation device can be used in
some cases [11], presenting the advantage of being
very robust to sustain possible rapid lesion growth, but
it is an invasive procedure at risk for this patient profile,
making more complex further radiation therapy and requir-
ing temporary chemotherapy cessation. Other techniques
are reported in the literature such as triple screwing com-
bined to cementoplasty [12, 13] or femoroplasty with or
without needle prior insertion [14]. However, the products
used in these techniques are not indicated for prophylactic
fixation, and these attempts are not standardized methods.
An alternative implantable device, Y-STRUT® (Hypreven-
tion), has been developed in these indications. It is a
medical device that is to be implanted during a minimally
invasive procedure in the proximal femur in order to
enhance its biomechanical performance and prevent
hip fracture.
A multicentre, single-arm, prospective study was initi-
ated in order to assess the Y-STRUT® medical device in
an orthopaedics-traumatology indication—prevention of
contralateral hip fracture following a first pertrochan-
teric fracture—and in an oncologic indication—impeding
pathological fracture prevention due to metastatic lesion
located in the neck or trochanter.
Methods
Ethical considerations
All procedures were performed according to the Declar-
ation of Helsinki, and the Human Ethics Committee of the
concerned countries approved all procedures used. Initial
clinical investigation plans and substantial amendments
were reviewed by ethics committees as requested by the
French and Belgian regulations. Initial protocols and
substantial changes were authorized by the Competent
Authorities from the participating Member States (ANSM
(Agence Nationale de Sécurité du Médicament et des
produits de santé) in France and AFMPS (Agence




A total of 15 patients were planned to be included in
this cohort. The patients were recruited on arrival to
the emergency room following a low-energy trauma
(fall from the patient’s height, fall from the bed, missed
stair steps, etc.) leading to a pertrochanteric fracture.
The main inclusion criteria were sex (only women
selected), age (between 60 and 90 years old) and osteo-
porosis (suspicious or known and defined by a T-score
inferior or equal to −2.5). The patients underwent the
surgical procedure within 24 to 72 h following their
admission.
Oncologic cohort
A total of 10 procedures were planned. The patients
were selected during multidisciplinary consultation
meetings between oncologists, orthopaedic surgeons and
interventional radiologists. The main inclusion criteria
were patients with lytic lesions located in the proximal
femur, with a size inferior or equal to two thirds of the
cortex, and having a high risk of pathological hip fracture
defined by a Mirels score superior or equal to 8 [15]. Once
included, the patients had the procedure planned and
performed in the interventional radiology department
within the two following weeks.
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Investigational device description
The Y-STRUT® device was designed to provide a
prophylactic reinforcement of the proximal femur. It
is an alternative implantable device which consists of
two implants made of a radiotransparent PEEK polymer
material. These implants connect in situ (Fig. 1) and work
in combination with polymethyl methacrylate (PMMA)-
type bone cement. Perforated implants allow controlled
injection of the cement (see Fig. 1). The cement aims to
increase the surface contact between the bone and the
device and to anchor the device in the proximal femur. It
is also used to fill the lytic lesions, if any.
The consolidation of the femoral head by the implantable
medical device was studied through biomechanical tests in
vitro, on human femurs, in order to simulate falls on ana-
tomical pieces. This study demonstrated the potential of Y-
STRUT® to improve the biomechanical performance of the
proximal femur. Implant insertion seems to be relevant to
support multiple falls and, thus, to prevent a second hip
fracture in elderly patients. As the studied device is not
intended to be used as a fracture fixation osteosynthesis
system, but as a preventive reinforcement in case of
osteoporosis or localized osteolytic lesion, its mechan-
ical performance was not designed to be compared to
existing fracture fixation devices (short femoral nail or
compression hip screw).
Operative technique
The two implants composing the device are inserted
through a minimally invasive procedure under imaging
control. The dedicated instrumentation ensures the
connection between the two components with a min-
imally invasive approach (Fig. 2). The technique con-
sists in introducing a guide wire in the axis of the
femoral neck to direct the drilling for the implant 1. A
pilot, on which work tubes are assembled, enables the
guidance of the second drill to connect the 2 compo-
nents of the device. The device is finally fixed into bone
with PMMA cement injected through the implants.
In this study, all procedures were performed under
general anaesthesia.
Specifications for osteoporotic cohort
Prophylactic consolidation with the implantable medical
device was performed contralaterally by orthopaedic sur-
geons, after surgical treatment of the pertrochanteric frac-
ture on the opposite side and under the same anaesthesia.
The patients were in a supine position on the orthopaedic
traction table. A bioactive PMMA radio-opaque bone ce-
ment at low temperature of polymerization (CORTOSS®,
Stryker) was used.
Specifications for oncologic cohort
All oncologic procedures were performed by interven-
tional radiologists in this indication, with a similar
operative technique and identical instrumentation kit.
The patients were either in a supine position or in a
lateral position maintained by a scoop stretcher. Lytic
femoral lesions of the patients were filled while cement
was injected through the implant at the last stage of the
procedure (Fig. 3). The patients received OPACITY+®
cement (TEKNIMED) or F20® cement (TEKNIMED).
Both are PMMA radio-opaque bone cements at high
temperature of polymerization.
Post-operative protocol and follow-up
No specific rehabilitation was needed. Full weight
bearing on the Y-STRUT® implanted leg and walking
recovery were allowed the day following the interven-
tion. The patients from the osteoporotic cohort had to
follow the rehabilitation protocol prescribed for their
fracture. A 5-year-long follow-up is planned, with
short-term (3 weeks, 3 months and 6 months), mid-
term (12 months) and long-term (2, 3, 4 and 5 years)
assessments for the osteoporotic cohort. A 1-year-long
follow-up is planned for the oncologic cohort, with
short-term (2 and 6 months) and mid-term (12 months)
assessments.
Patients were followed by medical consultation and
radiographic exams.
Fig. 1 Y-STRUT® implants (schematic and x-ray views)
Fig. 2 Percutaneous approach
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Data analysis
The investigators committed to follow the protocols in
all respects particularly in regard to obtaining consent,
following patients and reporting serious adverse events.
All investigation variables were collected using electronic
Case Report Forms (CS Online, Clinsight), and a quality
control of the database was done to confirm the overall
integrity of the data. Adverse events, medical history
and associated treatments were coded using the MedDRA
and the WHO Drug Dictionaries. A questionnaire to
be completed by the physicians performing the inter-
ventions was used to assess the technical feasibility of
each operative step.
Endpoints
Common and primary objectives of these two investi-
gations were to assess the procedure feasibility and
safety as well as the short-term and mid-term toler-
ance of Y-STRUT®.
Evaluation of the procedure feasibility and safety was
based on procedural parameters: technical difficulties
(on a scale from 1 to 5), patient’s positioning, operating
time (skin to skin), hospitalization stay and quantity of
cement, and on intraoperative adverse events, including
cement leakage, implantation failure or any other event
likely to impact the benefit of the procedure and/or to
present a risk for the patient.
Six short- and medium-term tolerance device criteria
were defined: walking recovery at short-term (and
plantar pressure for the osteoporotic cohort), pain
evaluation using a visual analogue scale (VAS) at each
follow-up visit, overall patients’ condition assessment
using Oxford Hip Score (OHS-12), osteointegration
and stability of the device by radiographic control,
adverse events possibly related to the device or its
implantation and device explantation.
Secondary endpoints focused on the mid-term efficacy
and included low-energy falls and fractures reported
during post-operative follow-up.
Statistical and quantitative assessments
The statistical analysis was performed using SAS version
9.3 (SAS Institute, NC, USA). Quantitative variables were
described using mean, standard deviation (SD), median and
range. Qualitative variables were described using frequen-
cies and percentages of each modality. Number of patients
and number of missing data were given for each variable.
Results
Patients
Four patients out of a total of 15 planned were im-
planted in the osteoporotic cohort. Patient inclusion is
still ongoing. The patients, all female per protocol, were
on average 83 years old (range 81 to 86) and in a severe
osteoporotic condition, as confirmed by a mean T-score
of −3.30 (range −3.8 to −2.7) measured at 3 months. The
10-year probability of hip fracture was calculated for
each patient at discharge by using the FRAX® tool (Fracture
Risk Assessment Tool). Results indicated a mean risk of
22% (range 10 to 37).
Twelve patients were included in the oncologic cohort.
Patients (8 males, 4 females) were all somewhat ambula-
tory (with a mean ECOG (Eastern Cooperative Oncology
Group) score of 1.4; range 0 to 3) and presented with
impending pathologic fracture at baseline (as indicated by
a median Mirels score of 9 (range 8 to 11)). Primary can-
cers were lung (n = 5), kidney (n = 2) or a variety of other
primary cancers (n = 5). It is to be noted that 2 patients
experienced femoral fracture prior to the intervention; in
accordance with the protocol, they were not implanted;
they were excluded from post-operative results.
Technical feasibility
Results showed that all procedural steps were found
either “easy” or “very easy” in most cases, demonstrating
the technical feasibility of the procedure despite the
novelty of the intervention and the limited physician
experience (each of the 8 treating physicians performed
less than 2 interventions on average).
Fig. 3 Radiotransparent implant has been implemented. The bone metastasis is being filled with PMMA bone cement
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In the osteoporotic cohort, all the procedures were
performed by orthopaedic surgeons, in a supine position
on the orthopaedic traction table. The mean volume of
cement injected was 7.3 ml (range 6 to 10 ml), and the
mean duration of the intervention was 48 ± 15 min
(range 35 to 65 min) (Table 1).
In the oncologic cohort, all the procedures were
performed by interventional radiologists. The patients were
in a supine position (50%) or in a lateral position (50%) on
an angiographic table, in an angio-suite. The mean volume
of cement injected was 9.2 ml (range 3 to 15 ml), and the
mean duration of intervention was 97 ± 28 min (range 60
to 155 min) (Table 2).




Average follow-up duration was 461 days (range 213 to
945 days).
Duration of hospitalization was not lengthened by the
additional implantation. The mean duration was 17.0 days
(range 5 to 25 days). All patients had recovered their walk-
ing ability at discharge. At 3 weeks and 3, 6 and 12 months,
comparison between the two legs’ plantar pressures
revealed no differences.
The mean pain was 0.9 (range 0.5 to 2) at 3 weeks
(Table 1). A high pain was reported for 1 patient, due to
a cement leakage. Pain was resolved by the removal of the
excess cement. Evolution of OHS-12 score was reported for
a single patient with an OHS-12 of 18 at 3 months (severe
condition) and of 43 at 2 years (satisfactory condition).
Wound healing was achieved for all patients. No osteolysis
nor implant loosening was observed at the different follow-
ups. No fracture occurred among this cohort.
Oncologic patients
During the follow-up, 6 patients (60%) deceased from
severe progression of their underlying cancer after a
mean follow-up of 142 days (range 24 to 324 days)—there
was no other cause of death reported. Among the survival
patients, the average follow-up duration was 305 days
(range 246 to 393 days).
The mean duration of hospitalization was 2.3 days (range
1 to 5 days—1 patient suffered from a severe progression of
his cancer and deceased 24 days after the implantation
while he was still hospitalized; he was excluded from this
statistical calculation), and 4 of the 10 patients (40%) were
discharged the day following the intervention.
No cement leakage was observed. Wound healing was
achieved in all cases with no access site complication.
Eight out of 9 patients (89%) could resume walking
after the intervention. The patient who did not recover
walking was the only one presenting an ECOG score of
3 before intervention (meaning more than 50% of time
in bed during the day and symptomatic).
The average pain at baseline was 3.6 ± 2.9, with no
evolution at discharge with an average pain of 3.4 ± 2.6.
However, at 2 months, pain relief was observed with an
average pain of 2.4 ± 0.9 (Table 2). One patient com-
plained from pain at the level of the implant entry site in
the bone immediately after the procedure. The pain was
spontaneously resolved at 3 weeks follow-up. No signifi-
cant change was observed in OHS-12 results at baseline,
2 months and 6 months (average total score of 30, 28
and 32, respectively).
One patient was diagnosed at 6 months follow-up with
an asymptomatic femoral neck fracture associated with a
fracture of the implant. This event may be attributed to
tumour progression and non-optimal placement of the
Y-STRUT® implant (non-compliant with the instructions
for use), too close to the superior cervical cortex which
might weaken the bone. The patient underwent ortho-
paedic surgery on the same day to explant the device and
treat the fracture, without further related complications.







1-1 35 5 2
1-2 35 19 0
1-3 58 17 0.5
1-4 65 27 1














2-1 75 24b 9 NA NA
2-2a NA NA NA NA NA
2-3 60 2 2 2 2
2-4 132 1 3 0 3
2-5 155 3 3 3 3
2-6 91 1 0 4 3
2-7 105 5 8 8 Missing
2-8a NA NA NA NA NA
2-9 90 1 2 Missing 3
2-10 75 3 Missing Missing 1
2-11 110 4 4 6 3
2-12 85 1 1 1 1
Mean 97 2.3 3.6 3.4 2.4
NA Not applicable
aCancelled due to pre-operative fracture
bPatient deceased while she was still hospitalized. Excluded from statistical
calculation of the hospitalization duration
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Discussion
The technical feasibility was demonstrated with a
favourable assessment achieved in both cohorts. Minim-
ally invasive procedure is a real need in prophylaxis to
avoid any risk of infection and to get rapid recovery, as
well for osteoporotic patients who already undergo a more
invasive fixation fracture intervention with the inherent
risks, as for oncologic patients with poor performance
status and life expectancy and who are not candidates for
a surgery. In both indications, no bleedings nor infection
was related to the Y-STRUT® implantation.
Y-STRUT® has the advantage of being specifically
developed for prophylactic fixation, as shown through
the biomechanical evaluation [16]. It is made of polymer,
thus allowing an adequate stress distribution into the bone
to achieve reinforcement. To our knowledge, osteosynthesis
devices are neither indicated nor used for prophylaxis in
osteoporotic patients. They are made of titanium or
stainless steel that make them strong enough to fix a frac-
ture and could be used to reinforce the bone, but they are
invasive, may be painful for a prophylactic fixation and
may require a longer hospitalization than Y-STRUT® [11].
However, in oncology, in the case of large lesions affecting
the diaphysis, intramedullary nails are still indicated. Y-
STRUT® is only indicated in the case of small lesions
located in the trochanter or the femoral neck when the
implant placement will allow reinforcement.
The mean duration of intervention, skin to skin, was
48 ± 15 min when performed by orthopaedic surgeons.
The lengthening of the anaesthetic for the concerned
patients (additional to the one needed for the fracture
treatment for pre-operative patient preparation and de-
vice implantation) did not lead to any adverse events. In
oncology, the feasibility of the Y-STRUT® implantation
by interventional radiologists was shown. The mean dur-
ation was 97 ± 28 min, slightly shorter than the 110 ±
43 min reported by Deschamps et al. [13] in their cohort
of 35 patients. Tian et al. [14] reported a little shorter
duration with a mean of 80 ± 7.5 min in a cohort of 19
patients, for the insertion of 4 modified trocar needles
combined with cementoplasty. Compared to these tech-
niques, the Y-STRUT® implantation has the advantage
to be based on a dedicated instrumentation kit which
ensures the reproducibility of the technique. The longest
implantation duration for interventional radiologists can
be explained by the time-consuming CT scans performed
during the procedure. Moreover, procedures for both indi-
cations were performed by 9 different practitioners, and
duration should be significantly improved with a learning
curve. Over time, implantation duration should not be
longer than the one for a standard osteosynthesis device.
As expected, the total quantity of cement injected in
Y-STRUT® was lower in the osteoporotic patients than
in the oncologic patients (7.3 ± 1.9 ml versus 9.2 ± 3.1 ml,
respectively). Indeed, in oncology, where the cement was
also used to fill the lytic lesion, the quantity of cement
injected (mean 9.2 ± 3.1 ml) increased significantly with
the Mirels score, which takes the size of the lesion into
account. These figures appear relatively low when com-
pared to the volumes of 36 and 47 ml injected alone by
Heini et al. [6] and Sutter et al. [7], respectively, to
reinforce osteoporotic bones by femoroplasty in cadaveric
studies and to the volume of 31 ml injected by Tian et al.
[14] in metastatic bone lesions treated by internal fixation
with needles plus cementoplasty. It is similar to the vol-
ume of 6 ml (range 3 to 10 ml) injected during triple
screwing combined with cementoplasty [13] for the same
indication but with 20% of cement leakage reported com-
pared to only 1 case (7%) with Y-STRUT® in this study.
Moreover, the limited amount of cement injected when
implanting Y-STRUT® provides favourable conditions if a
future explantation and revision are necessary.
In the osteoporotic cohort, the average duration of
hospitalization was 17.0 ± 9.1 days. It was related to the
hip fracture treatment and was not lengthened by the
Y-STRUT® implantation. For the oncologic cohort, the
average hospitalization was 2.3 ± 1.4 days (range 1 to
5 days), a little shorter than the duration of 3.1 days
(range 1 to 8 days) reported in a cohort of 35 oncologic
patients after triple screwing fixation [13]. These dura-
tions appear very short when compared to the 19.3 days
(range 1 to 105 days) reported by Ristevski et al. [11] in
a cohort of 201 patients for prophylactic treatment of
femoral metastatic lesions with a fracture fixation system
such as intramedullary nailing, showing the interest of a
minimally invasive technique. In addition, it should be
noted that 4 of the 10 patients from the study in the onco-
logic indication (40%) were discharged the day following
the intervention, suggesting that the Y-STRUT® implant-
ation could be performed as a day-surgery procedure.
For osteoporotic patients, average pain at the Y-STRUT®-
implanted hip was 0.9 (range 0.5 to 2) at 3 weeks follow-up,
indicating a very good short-term tolerance of the device.
More patients are needed to assess the mid-term pain
evolution and must show that prophylaxis does not lead
to any local pain. All patients could resume walking after
implantation with a good balance. The amount of missing
data for OHS-12 scores does not allow to draw conclu-
sions on the overall patients’ outcome. However, no
fracture was recorded after a mean follow-up of 461 days
(range 213 to 945 days).
In oncologic patients, overall patients’ condition, eval-
uated with OHS-12, remains stable (average total score
of 30, 28 and 32 at baseline, 2 months and 6 months,
respectively). All patients presenting an ECOG score
inferior to 3 at baseline (89%) could resume walking
after the intervention. A mean pain relief from 3.9 ± 2.9
at baseline to 2.4 ± 0.9 at 2 months was observed. Two
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patients pre-included in the oncologic cohort experi-
enced femoral fracture prior to the intervention; in
accordance with the protocol, they were neither included
nor treated and therefore not followed. However, these
pre-operative fractures confirm the validity of the eligibility
criteria and illustrate the severity of the patients’ condition
in this indication. In addition, 1 case of post-operative
fracture at 6 months was reported for an oncologic pa-
tient that may be attributed to tumour progression and
non-compliant placement of the Y-STRUT® implant.
Similarly, triple screwing plus cementoplasty treatment
technique [13] led to 2 cases (6%) of post-operative
pathological fractures at 3 weeks and 7 months. However,
with cementoplasty alone, a higher fracture rate (24%) was
reported in a cohort of 21 patients [14], which tends to
show the lower efficacy of this technique.
Limitations of the study include a small patient sample
(14 patients implanted with the studied device) and a
short follow-up (mean follow-up is 383 days among the
survival patients when the cohorts are combined). Never-
theless, the presented data is sufficient to evaluate the
feasibility of the procedure. Additional studies should be
conducted on a greater number of patients and with a
longer follow-up to confirm the clinical benefits of the
Y-STRUT® implantation in both indications.
Conclusions
Preliminary results from these first-in-man studies
demonstrate the feasibility, safety and tolerance of the
Y-STRUT® implantation. This procedure is associated
with a dedicated material and a controlled operative
technique, compared to existing non-standardised percu-
taneous techniques. Y-STRUT® represents a promising con-
solidation technique in two clinical indications: (1) for
patients suffering from bone fragility, it addresses a com-
mon issue with a new specific approach easy to implement,
with immediate effect contrary to existing treatments; the
procedure can be performed during the same anaesthetic
than the fracture fixation one without delaying the patient
recovery, and (2) for oncologic patients, whom general
status is often a contra-indication to a prophylactic consoli-
dation with a more invasive osteosynthesis fixation system,
this percutaneous treatment is an interesting alternative for
localized lytic lesion of the proximal femur.
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